...
首页> 外文期刊>Pharmaceutical patent analyst >Doctrine of equivalents in Japan - criteria of special conditions and estoppel: final conclusion
【24h】

Doctrine of equivalents in Japan - criteria of special conditions and estoppel: final conclusion

机译:日本等同物的学说 - 特殊条件和estoppel的标准:最终结论

获取原文
获取原文并翻译 | 示例
           

摘要

DKSH Japan KK, Iwaki Seiyaku Co. Ltd, Takata Pharmaceutical Co. Ltd and POLA-Pharma,-v. Chugai Pharmaceutical Co, Ltd and The Trustees of Columbia University in the City of New York, decision by the Supreme Court of Japan (Heisei 28 [ju] 1242) dated 24 March 2017 [1].The Supreme Court of japan maintained a 'drastic' principle of the Doctrine of Equivalence (DoE) held by the Intellectual Property High Court decision in 2016 [2,3]. This is the case about a patent infringement case between Chugai (the patentee), a subsidiary of F Hoffmann-La Roche AG and the four generic drug makers including DKSH Japan KK. The case is directed to whether the DoE may be applied to a process of manufacture of an active pharmaceutical ingredient. Specifically, it was argued that the patent (Japanese Patent Number 3310301) claims a method of manufacture of a vitamin D derivative. As the generic drug makers employed trans-type vitamin D structure as a starting material and an intermediate thereof, whereas the patent claims literally only recite cis-xype vitamin D structure as a starting material and an intermediate thereof.
机译:Dksh Japan Kk,Iwaki Seiyaku Co. Ltd,Takata Pharmaceutical Co. Ltd和Pola-Pharma,-V。陈迈制药有限公司和哥伦比亚大学的哥伦比亚大学的受托人,由日本最高法院的决定(Heisei 28 [ju] 1242)于2017年3月24日[1]。日本最高法院维持'剧烈2016年知识产权高法庭决定持有的等价原则(DOE)[2,3]。这是关于Chugai(专利权人)的专利侵权案例,F Hoffmann-La Roche AG的子公司以及包括Dksh Japan KK的四个通用药物制造商。这种情况涉及DOE是否可以应用于活性药物成分的制造方法。具体地,认为该专利(日本专利3310303030303)要求制备维生素D衍生物的方法。随着通用药物制造商使用反式型维生素D结构作为起始材料和其中间体,而专利权利要求字面仅叙述Cis-Xype维生素D结构作为起始材料和中间体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号